A randomized controlled trial of two chemotherapy regimens (paclitaxel liposome combined with platinum and paclitaxel combined with platinum) in concurrent chemoradiotherapy for cervical carcinoma

• Published in: Zhōnghuá zhŏngliú zázhì Vol. 33; no. 7; p. 517
• Main Authors: Zeng, Si-yuan, Li, Ling, Zhong, Mei-ling, Jiang, Wei, Wu, Yun-yan, Liu, Yi
• Format: Journal Article
• Language: Chinese
• Published: China 01.07.2011
• Subjects: Adenocarcinoma - pathology; Adenocarcinoma - therapy; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Brachytherapy; Carboplatin - administration & dosage; Carboplatin - adverse effects; Carcinoma, Squamous Cell - pathology; Carcinoma, Squamous Cell - therapy; Chemoradiotherapy; Cisplatin - administration & dosage; Cisplatin - adverse effects; Cobalt Radioisotopes - therapeutic use; Exanthema - chemically induced; Female; Follow-Up Studies; Gastrointestinal Diseases - chemically induced; Humans; Iridium Radioisotopes - therapeutic use; Liposomes - administration & dosage; Liposomes - adverse effects; Middle Aged; Neoplasm Staging; Paclitaxel - administration & dosage; Paclitaxel - adverse effects; Remission Induction; Survival Rate; Uterine Cervical Neoplasms - pathology; Uterine Cervical Neoplasms - therapy
• ISSN: 0253-3766
• DOI: 10.3760/cma.j.issn.0253-3766.2011.07.009

To compare the efficacy, side effects and influence of two chemotherapy regimens, paclitaxel liposome combined with platinum and paclitaxel combined with platinum, on the survival rate in patients with cervical carcinoma receiving concurrent chemoradiotherapy. One hundred and sixty two cases with primary cervical carcinoma diagnosed and treated in the Jiangxi Maternal and Children Hospital between January 2008 and November 2009 were enrolled in this randomized controlled trial. Seventy one cases were included in the paclitaxel group and 91 in the paclitaxel liposome group. The chemotherapy doses were as followings: paclitaxel liposome and paclitaxel 135 mg/m(2); cisplatin 80 mg/m(2) or carboplatin AUC 4 - 6, repeated every 21 days for two or three times. Radical radiotherapy was given to both groups at the same time. The efficacy was evaluated by the tumor regression and the patients were followed-up for six months. The overall response rates of paclitaxel group and paclitaxel liposome group were 90.1% and 89